4 not yet recruiting, 3 unknown, 2 recruiting, 1 completed. 10 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Not yet recruiting 4, Unknown 3, Recruiting 2, Completed 1 |
| Phase 1 | 5 | Not yet recruiting 3, Recruiting 1, Unknown 1 |
Follow PTCL: new trials by email Literature Review of PTCL trials Research Report on PTCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma FG-M131 - PTCL, TRBC1 ADC | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 110 | 2026-08-30 | 2026-09-02 |
| SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) SHR2554 combined with Liposomal Mitoxantrone - PTCL, First Line Treatment | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2026-08-01 | 2026-07-24 |
| Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL Zeprumetostat+Azacitadine, Zeprumetostat+Decitabine, Zeprumetostat+Chidamide - PTCL, Refractory | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 86 | 2026-03-23 | 2026-04-07 |
| SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma SHR2554 Tablets - PTCL | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 30 | 2026-02-01 | 2026-01-16 |
| Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL CD5-targeted CAR-T cells - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 30 | 2025-02-14 | 2026-05-07 |
| Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma Toripalimab, chidamide - PTCL | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 43 | 2024-04-03 | 2024-07-09 |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma YY-20394 treatment - PTCL | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 90 | 2021-04-01 | 2021-01-12 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Azacytidine, Romidepsin, Belinostat - PTCL | Phase 2 | Recruiting | University of Virginia | 50 | 2021-02-19 | 2026-01-21 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Tislelizumab - Peripheral T Cell Lymphoma, PTCL | Phase 2 | Completed | BeiGene | 77 | 2018-04-13 | 2024-10-26 |
Lymphoma, T-Cell (2) · Immunoblastic Lymphadenopathy (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphadenopathy (1) · Pathologic Processes (1)
10-propargyl-10-deazaaminopterin (1) · Azacitidine (1) · Cyclophosphamide (1) · Doxorubicin (1) · Gemcitabine (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Vincristine (1) · belinostat (1) · parsaclisib (1) · romidepsin (1) · tislelizumab (1) · toripalimab (1)
BeiGene (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Peking University People's Hospital (1) · Ruijin Hospital (1) · Shanghai YingLi Pharmaceutical Co. Ltd. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Virginia (1)
China (5) · Canada (1) · France (1) · Italy (1) · Taiwan (1) · United States (1)
Craig Portell, MD (1) · Junning Cao (1)
2017 (1)